Abstract:Amyloid-β (Aβ), the influence of which is considered the pathomechanism of Alzheimer’s disease, is also present in healthy people. The microbiome’s impact is also taken into account, where bacterial lipopolysaccharide (LPS) activates inflammatory processes and stimulates microglia via TLRs. Molecules of bacterial origin can co-create senile plaques with Aβ. This study evaluated the activity of physiological Aβ concentrations on neuronal and microglial cells after preincubation with LPS. Two cell lines were use… Show more
“…At higher concentrations, Aβ25-35 caused adverse effects. The physiological concentrations of Aβ25-35 showed neuroprotective and neurotrophic effects similar to those observed in our previous study [32]. These findings seem to be in line with the recent shift in the perception of amyloid β, from the purely pathological and hallmark of disease to a potential antimicrobial peptide necessary for the brain's proper functioning [33,34].…”
Section: Neuronal Features Of Pc12 Cells After Incubation With Aβ25-35 or Lpssupporting
confidence: 89%
“…In our opinion, the time of differentiation should be at least 72 h [15]. Therefore, the time of 72 h was chosen in this study, examining the effect of differentiation on sensitivity to harmful factors (LPS and Aβ [25][26][27][28][29][30][31][32][33][34][35].…”
Section: Pc12 Cells and Amyloid β (25-35)mentioning
confidence: 99%
“…3.6. THP-1 Cells and Amyloid β (25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35) Incubation of THP-1 cells with amyloid β (25-35) caused a significant decrease in mitochondrial metabolic activity (measured in the MTT assay) in all tested cases except for 0.001 μM Aβ25-35 concentration in differentiated cells (up to 16.4% or 15.2% at 5 μM Aβ25-35, respectively). However, the differences depending on cell differentiation were small and statistically insignificant (Figure 7A).…”
Section: Thp-1 Cells and Amyloid β (25-35)mentioning
Models based on cell cultures have become a useful tool in modern scientific research. Since primary cell lines are difficult to obtain and handle, neoplasm-derived lines like PC12 and THP-1 offer a cheap and flexible solution for neurobiological studies but require prior differentiation to serve as a neuronal or microglia model. PC12 cells constitute a suitable research model only after differentiation by incubation with nerve growth factor (NGF) and THP-1 cells after administering a differentiation factor such as phorbol 12-myristate-13-acetate (PMA). Still, quite often, studies are performed on these cancer cells without differentiation. The study aimed to assess the impact of PC12 or THP-1 cell differentiation on sensitivity to harmful factors such as Aβ25-35 (0.001–5 µM) (considered as one of the major detrimental factors in the pathophysiology of Alzheimer’s disease) or lipopolysaccharide (1–100 µM) (LPS; a pro-inflammatory factor of bacterial origin). Results showed that in most of the tests performed, the response of PC12 and THP-1 cells induced to differentiation varied significantly from the effect in undifferentiated cells. In general, differentiated cells showed greater sensitivity to harmful factors in terms of metabolic activity and DNA damage, while in the case of the free radicals, the results were heterogeneous. Obtained data emphasize the importance of proper differentiation of cell lines of neoplastic origin in neurobiological research and standardization of cell culture handling protocols to ensure reliable results.
“…At higher concentrations, Aβ25-35 caused adverse effects. The physiological concentrations of Aβ25-35 showed neuroprotective and neurotrophic effects similar to those observed in our previous study [32]. These findings seem to be in line with the recent shift in the perception of amyloid β, from the purely pathological and hallmark of disease to a potential antimicrobial peptide necessary for the brain's proper functioning [33,34].…”
Section: Neuronal Features Of Pc12 Cells After Incubation With Aβ25-35 or Lpssupporting
confidence: 89%
“…In our opinion, the time of differentiation should be at least 72 h [15]. Therefore, the time of 72 h was chosen in this study, examining the effect of differentiation on sensitivity to harmful factors (LPS and Aβ [25][26][27][28][29][30][31][32][33][34][35].…”
Section: Pc12 Cells and Amyloid β (25-35)mentioning
confidence: 99%
“…3.6. THP-1 Cells and Amyloid β (25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35) Incubation of THP-1 cells with amyloid β (25-35) caused a significant decrease in mitochondrial metabolic activity (measured in the MTT assay) in all tested cases except for 0.001 μM Aβ25-35 concentration in differentiated cells (up to 16.4% or 15.2% at 5 μM Aβ25-35, respectively). However, the differences depending on cell differentiation were small and statistically insignificant (Figure 7A).…”
Section: Thp-1 Cells and Amyloid β (25-35)mentioning
Models based on cell cultures have become a useful tool in modern scientific research. Since primary cell lines are difficult to obtain and handle, neoplasm-derived lines like PC12 and THP-1 offer a cheap and flexible solution for neurobiological studies but require prior differentiation to serve as a neuronal or microglia model. PC12 cells constitute a suitable research model only after differentiation by incubation with nerve growth factor (NGF) and THP-1 cells after administering a differentiation factor such as phorbol 12-myristate-13-acetate (PMA). Still, quite often, studies are performed on these cancer cells without differentiation. The study aimed to assess the impact of PC12 or THP-1 cell differentiation on sensitivity to harmful factors such as Aβ25-35 (0.001–5 µM) (considered as one of the major detrimental factors in the pathophysiology of Alzheimer’s disease) or lipopolysaccharide (1–100 µM) (LPS; a pro-inflammatory factor of bacterial origin). Results showed that in most of the tests performed, the response of PC12 and THP-1 cells induced to differentiation varied significantly from the effect in undifferentiated cells. In general, differentiated cells showed greater sensitivity to harmful factors in terms of metabolic activity and DNA damage, while in the case of the free radicals, the results were heterogeneous. Obtained data emphasize the importance of proper differentiation of cell lines of neoplastic origin in neurobiological research and standardization of cell culture handling protocols to ensure reliable results.
“…Previously, our study displayed that major inflammatory cytokines, IL-12, and IFN-γ in brain of transgenic mice APP SWE (Tg2576) that overexpress the human Aβ precursor protein gene as an AD mouse model were associated with Aβ plaque formation and microglial and astrocyte activation (Abbas et al, 2002). In the brains of patients with AD and its animal models, infection stimulating microglia and/or microglial activation by peripheral cytokines caused robust production of free radicals with another wave of pro-inflammatory cytokines, which, in turn, led to inflammation and massive neuronal damage (Nakamura et al, 2021;Wiatrak and Balon, 2021).…”
Alzheimer’s disease as the most common age-related dementia affects more than 40 million people in the world, representing a global public health priority. However, the pathogenesis of Alzheimer’s disease (AD) is complex, and it remains unclear. Over the past decades, all efforts made in the treatments of AD, with targeting the pathogenic amyloid β (Aβ), neurofibrillary tangles, and misfolded tau protein, were failed. Recently, many studies have hinted that infection, and chronic inflammation that caused by infection are crucial risk factors for AD development and progress. In the review, we analyzed the role of infections caused by bacteria, viruses, and other pathogens in the pathogenesis of AD and its animal models, and explored the therapeutic possibility with anti-infections for AD. However, based on the published data, it is still difficult to determine their causal relationship between infection and AD due to contradictory results. We think that the role of infection in the pathogenesis of AD should not be ignored, even though infection does not necessarily cause AD, it may act as an accelerator in AD at least. It is essential to conduct the longitudinal studies and randomized controlled trials in humans, which can determine the role of infection in AD and clarify the links between infection and the pathological features of AD. Finding targeting infection drugs and identifying the time window for applying antibacterial or antiviral intervention may be more promising for future clinical therapeutic strategies in AD.
“…To evaluate the impact of SVT-LCNs on cell viability, human monocyte-derived macrophages THP-1 were used. These cells are widely accepted as the surrogate of microglial cells to evaluate cytokine secretion in the context of neuroinflammation in AD (McFarland et al, 2017;Wiatrak and Balon, 2021). THP-1 monocytes were cultured in RPMI 1640 medium supplemented with 10% FCS at 37°C in 5% CO 2 .…”
Section: Effect Of Svt-lcns On Pro-inflammatory Glia-like Cell Viabilitymentioning
Nasal delivery has been indicated as one of the most interesting alternative routes for the brain delivery of neuroprotective drugs. Nanocarriers have emerged as a promising strategy for the delivery of neurotherapeutics across the nasal epithelia. In this work, hybrid lecithin/chitosan nanoparticles (LCNs) were proposed as a drug delivery platform for the nasal administration of simvastatin (SVT) for the treatment of neuroinflammatory diseases. The impact of SVT nanoencapsulation on its transport across the nasal epithelium was investigated, as well as the efficacy of SVT-LCNs in suppressing cytokines release in a cellular model of neuroinflammation. Drug release studies were performed in simulated nasal fluids to investigate SVT release from the nanoparticles under conditions mimicking the physiological environment present in the nasal cavity. It was observed that interaction of nanoparticles with a simulated nasal mucus decreased nanoparticle drug release and/or slowed drug diffusion. On the other hand, it was demonstrated that two antibacterial enzymes commonly present in the nasal secretions, lysozyme and phospholipase A2, promoted drug release from the nanocarrier. Indeed, an enzyme-triggered drug release was observed even in the presence of mucus, with a 5-fold increase in drug release from LCNs. Moreover, chitosan-coated nanoparticles enhanced SVT permeation across a human cell model of the nasal epithelium (×11). The nanoformulation pharmacological activity was assessed using an accepted model of microglia, obtained by activating the human macrophage cell line THP-1 with the Escherichia coli–derived lipopolysaccharide (LPS) as the pro-inflammatory stimulus. SVT-LCNs were demonstrated to suppress the pro-inflammatory signaling more efficiently than the simple drug solution (−75% for IL-6 and −27% for TNF-α vs. −47% and −15% at 10 µM concentration for SVT-LCNs and SVT solution, respectively). Moreover, neither cellular toxicity nor pro-inflammatory responses were evidenced for the treatment with the blank nanoparticles even after 36 h of incubation, indicating a good biocompatibility of the nanomedicine components in vitro. Due to their biocompatibility and ability to promote drug release and absorption at the biointerface, hybrid LCNs appear to be an ideal carrier for achieving nose-to-brain delivery of poorly water-soluble drugs such as SVT.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.